221 related articles for article (PubMed ID: 11896119)
41. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
[TBL] [Abstract][Full Text] [Related]
42. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H; Nielsen G
Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
[TBL] [Abstract][Full Text] [Related]
43. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
Vrooman LM; Neuberg DS; Stevenson KE; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Larsen EC; Laverdière C; Michon B; Schorin M; Schwartz CL; Cohen HJ; Lipshultz SE; Silverman LB; Sallan SE
Eur J Cancer; 2011 Jun; 47(9):1373-9. PubMed ID: 21514146
[TBL] [Abstract][Full Text] [Related]
44. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
45. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.
de Matos Neto RP; Petrilli AS; Silva CM; Campos Filho O; Oporto VM; Gomes Lde F; Paiva MG; Carvalho AC; Moisés VA
Arq Bras Cardiol; 2006 Dec; 87(6):763-71. PubMed ID: 17262115
[TBL] [Abstract][Full Text] [Related]
46. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
Huh WW; Jaffe N; Durand JB; Munsell MF; Herzog CE
Pediatr Hematol Oncol; 2010 Oct; 27(7):546-57. PubMed ID: 20795769
[TBL] [Abstract][Full Text] [Related]
47. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
[TBL] [Abstract][Full Text] [Related]
48. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry.
Foerster SR; Canter CE; Cinar A; Sleeper LA; Webber SA; Pahl E; Kantor PF; Alvarez JA; Colan SD; Jefferies JL; Lamour JM; Margossian R; Messere JE; Rusconi PG; Shaddy RE; Towbin JA; Wilkinson JD; Lipshultz SE
Circ Heart Fail; 2010 Nov; 3(6):689-97. PubMed ID: 20833772
[TBL] [Abstract][Full Text] [Related]
49. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
[TBL] [Abstract][Full Text] [Related]
50. Long-term outcomes of dilated cardiomyopathy diagnosed during childhood: results from a national population-based study of childhood cardiomyopathy.
Alexander PM; Daubeney PE; Nugent AW; Lee KJ; Turner C; Colan SD; Robertson T; Davis AM; Ramsay J; Justo R; Sholler GF; King I; Weintraub RG;
Circulation; 2013 Oct; 128(18):2039-46. PubMed ID: 24036608
[TBL] [Abstract][Full Text] [Related]
51. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
Cusack BJ; Young SP; Driskell J; Olson RD
Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
[TBL] [Abstract][Full Text] [Related]
52. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
53. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.
Kremer LC; Tiel-van Buul MM; Ubbink MC; Offringa M; Ottenkamp J; Olmos RV; Voûte PA
J Clin Oncol; 1999 Apr; 17(4):1208. PubMed ID: 10561180
[TBL] [Abstract][Full Text] [Related]
54. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
55. Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Lapointe MO; Caru M; Curnier D; Raboisson MJ; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Pediatr Hematol Oncol; 2023 Mar; 45(2):70-77. PubMed ID: 36161876
[TBL] [Abstract][Full Text] [Related]
56. Comparison of bolus administration and short-term infusion versus long-term infusion of doxorubicin in terms of cardiotoxicity and efficacy.
Ghiami H; Omidkhoda N; Seddigh-Shamsi M; Rahimi H; Arasteh O
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3771-3780. PubMed ID: 38095650
[TBL] [Abstract][Full Text] [Related]
57. Modelling cardiac mechanics in doxorubicin-induced cardiotoxicity following childhood acute lymphoblastic leukemia using a combination of cardiac magnetic resonance imaging, cardiopulmonary exercise testing and the CircAdapt model.
Artz T; Caru M; Curnier D; Abasq M; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Biomech; 2023 Jun; 154():111616. PubMed ID: 37207545
[TBL] [Abstract][Full Text] [Related]
58. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.
Schorin MA; Blattner S; Gelber RD; Tarbell NJ; Donnelly M; Dalton V; Cohen HJ; Sallan SE
J Clin Oncol; 1994 Apr; 12(4):740-7. PubMed ID: 8151317
[TBL] [Abstract][Full Text] [Related]
59. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
Furman WL; Stewart CF; Kirstein M; Kepner JL; Bernstein ML; Kung F; Vietti TJ; Steuber CP; Becton DL; Baruchel S; Pratt C
J Clin Oncol; 2002 Mar; 20(6):1617-24. PubMed ID: 11896112
[TBL] [Abstract][Full Text] [Related]
60. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity.
Waber DP; Silverman LB; Catania L; Mautz W; Rue M; Gelber RD; Levy DE; Goldwasser MA; Adams H; Dufresne A; Metzger V; Romero I; Tarbell NJ; Dalton VK; Sallan SE
J Clin Oncol; 2004 Jul; 22(13):2701-7. PubMed ID: 15226337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
